Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of subcutaneous DS002 for bone metastasis-related cancer pain
CTR20254189Phase 2Active
- Sponsor
- Dartsbio Pharmaceutical
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer pain comparing DS002 with Placebo (2 arms). Primary endpoint: Proportion of participants with at least a 2-point reduction from baseline in daily average pain intensity Numerical Rating Scale score at the designated bone metastasis pain site. Started Feb 2026; status: active.
02
Drugs
DS002
03
Conditions
cancer pain
Beyond the preview
Go deeper on CTR20254189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254189.